Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT01663272
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 659
- Registration Number
- NCT01658878
- Locations
- 🇺🇸
Local Institution - 0002, Ann Arbor, Michigan, United States
🇺🇸Local Institution - 0008, Los Angeles, California, United States
🇺🇸Local Institution - 0048, Washington, District of Columbia, United States
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT01639508
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: CabozantinibDrug: Androgen Ablation Therapy
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01630590
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
- Conditions
- PainProstate CancerCastration Resistant Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1028
- Registration Number
- NCT01605227
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
- Conditions
- Bone MetastasesRecurrent Prostate CancerStage IV Prostate CancerCastrate-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 19
- Registration Number
- NCT01599793
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Cabozantinib in Advanced Solid Malignancies
- Conditions
- Solid Tumor (Not Breast or Prostate Cancers)Lung Cancer
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT01588821
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT01582295
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
XL-184+Abiraterone in Post-Chemo CRPC
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01574937
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- Conditions
- Prostatic NeoplasmsCastration Resistant Prostate CancerPainProstate Cancer
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 119
- Registration Number
- NCT01522443
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.